Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2025 –2032 | |
|
|
USD 3.21 Billion |
| USD 5.47 Billion | |
| % | |
|
Global Dapagliflozin Market Segmentation, By Indication (Type 2 Diabetes Mellitus, Heart Failure (HFrEF), and Chronic Kidney Disease (CKD)), Dosage Strength (5 mg and 10 mg), Application (Monotherapy and Combination Therapy), Age Group (Adult and Geriatric), End User (Hospitals, Specialty Clinics, and Homecare Settings), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2032
Get Exclusive Sample Copy of this Report Here
The global dapagliflozin market is driven by the increasing prevalence of diabetes, heart failure, and chronic kidney disease (CKD). According to the International Diabetes Federation (IDF), approximately 537 million adults aged 20-79 were living with diabetes in 2021, with the number expected to rise to 643 million by 2030. Furthermore, heart failure affects over 64 million people globally, with nearly half showing reduced ejection fraction, a key indication for dapagliflozin use. Chronic kidney disease impacts nearly 10% of the global population, with millions remaining undiagnosed due to asymptomatic progression. The efficacy of dapagliflozin in managing glucose levels, reducing cardiovascular risks, and slowing CKD progression has positioned it as a critical therapeutic agent, particularly in regions with a high burden of these conditions, such as Asia-Pacific and North America.
Global dapagliflozin market size was valued at USD 3.21 billion in 2024 and is projected to reach USD 5.47 billion by 2032, with a CAGR of 6.70% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dapagliflozin Market Trends
“Rise in Generic Drug Development”
The expiration of patents for dapagliflozin is leading to the entry of generic drug manufacturers, resulting in increased availability of cost-effective alternatives. This trend is particularly pronounced in developing countries, where affordability is a key factor in medication accessibility. Generic versions are enabling wider distribution in regions with limited healthcare budgets, ensuring that more patients benefit from dapagliflozin's therapeutic effects. This shift is also fostering competition among manufacturers, contributing to reduced treatment costs and enhancing the reach of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in global markets.
Report Scope and Dapagliflozin Market Segmentation
|
Attributes
|
Dapagliflozin Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America
|
|
Key Market Players
|
AstraZeneca plc (U.K.), Bristol-Myers Squibb Company (U.S.), Pfizer Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Dr. Reddy's Laboratories Ltd. (India), Torrent Pharmaceuticals Ltd. (India), Zydus Lifesciences Ltd. (India), Cipla Limited (India), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Lupin Limited (India), Sanofi (France), Aurobindo Pharma Ltd. (India), Abbott (U.S.), Boehringer Ingelheim International GmbH (Germany), and Eli Lilly and Company (U.S.).
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Dapagliflozin Market Definition
Dapagliflozin is an SGLT2 inhibitor that aids in managing type 2 diabetes by preventing glucose reabsorption in the kidneys, leading to increased glucose excretion. It is also approved for use in patients with heart failure and chronic kidney disease, providing protective cardiovascular and renal effects.
Dapagliflozin Market Dynamics
Drivers
The increasing prevalence of chronic conditions such as diabetes, heart failure, and chronic kidney disease (CKD) is significantly influencing the demand for dapagliflozin. Type 2 Diabetes Mellitus affects approximately 537 million adults globally, a number projected to rise to 643 million by 2030, according to the International Diabetes Federation. Alongside this, heart failure impacts over 64 million people worldwide, with a substantial portion experiencing reduced ejection fraction, a condition for which dapagliflozin has proven beneficial. CKD, which affects about 10% of the global population, often remains undiagnosed until advanced stages, further highlighting the need for effective treatments. Dapagliflozin, an SGLT-2 inhibitor, is gaining traction due to its demonstrated efficacy in managing hyperglycemia, reducing cardiovascular risks, and slowing CKD progression. Its versatility in addressing multiple comorbidities positions it as a critical therapeutic option in regions with high disease burdens, particularly in Asia-Pacific and North America. For instance, in June 2024, according to an article published by NCBI, the number of people affected by diabetes in India has risen sharply, from 33 million in 2000 to 72 million in 2021, with projections indicating it could reach 125 million by 2045. This growing prevalence of diabetes is expected to drive demand for effective treatments and therapies, creating significant opportunities for the SGLT2 inhibitors market to expand in India.
Dapagliflozin's clinical efficacy and regulatory approvals for expanded indications have significantly boosted its adoption. Landmark trials such as DAPA-HF demonstrated its ability to reduce cardiovascular mortality and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF), even in non-diabetic individuals. Similarly, the DAPA-CKD trial highlighted its efficacy in slowing the progression of chronic kidney disease (CKD), reducing the risk of kidney failure, cardiovascular events, and mortality. These findings have positioned dapagliflozin as a multi-faceted therapy addressing both glycemic control and critical comorbidities. Regulatory approvals in major markets, including the U.S., Europe, and Japan, have further cemented its role in the management of heart failure and CKD, extending its use beyond the traditional diabetes patient base. This expanded clinical utility is transforming the drug into a cornerstone treatment across cardiology, nephrology, and endocrinology, driving its integration into clinical guidelines worldwide. In June 2024, according to an article published by AstraZeneca, AstraZeneca’s Farxiga (dapagliflozin) has received FDA approval to improve glycemic control in pediatric patients aged 10 and older with type-2 diabetes (T2D), following positive results from the T2NOW Phase III trial. Previously approved for adults, this expanded indication strengthens Farxiga’s market presence. This approval highlights its clinical efficacy and broadens its potential, acting as a key driver for increased adoption and use across diverse patient groups.
Opportunities
Advancements in personalized medicine offer a significant opportunity for dapagliflozin by allowing treatments to be tailored to individual patient profiles. As genetic and biomarker testing becomes more prevalent, healthcare providers can better understand a patient's unique genetic makeup and comorbid conditions, enabling more precise treatment decisions. For dapagliflozin, this means optimizing its use in patients with specific genetic markers or multiple chronic conditions, such as diabetes, heart failure, and chronic kidney disease. By identifying patients who may respond more favorably to dapagliflozin or require lower doses due to genetic factors, treatment outcomes can be improved, reducing side effects and enhancing efficacy. This approach could expand dapagliflozin’s use beyond traditional treatment regimens, particularly in populations with complex health profiles, thus broadening its market reach. As personalized medicine continues to evolve, dapagliflozin’s role in individualized care will likely grow, making it a key player in the future of chronic disease management.
Partnerships with healthcare systems and institutions to create integrated care models present a significant opportunity for dapagliflozin. By working with hospitals, specialty care centers, and insurance companies, dapagliflozin can become a key component of holistic treatment plans for patients with comorbidities such as diabetes, cardiovascular diseases, and chronic kidney disease (CKD). Integrated care models focus on providing coordinated care across multiple specialties, enhancing patient outcomes and ensuring comprehensive management of chronic conditions. This approach not only improves the quality of care but also reduces long-term healthcare costs by preventing complications and hospitalizations. As more health systems adopt integrated care strategies, dapagliflozin’s role as a versatile therapy addressing multiple comorbidities can increase. Collaborations with insurers could further promote its use by ensuring coverage for a broader range of patients, making it an essential part of managing chronic diseases in multidisciplinary settings. This can lead to broader adoption and sustained market growth.
Restraints/Challenges
The high cost of dapagliflozin remains a significant restraint in its global market, particularly in regions with limited healthcare coverage. While the drug offers substantial clinical benefits for conditions such as diabetes, heart failure, and chronic kidney disease, its price can create barriers to access, especially for patients in low- and middle-income countries. In these regions, healthcare budgets are often stretched, and out-of-pocket costs for patients can be prohibitively high. Even though the availability of generic versions in the future may help reduce costs, the initial high pricing continues to limit patient access to dapagliflozin, especially for those requiring long-term treatment. This financial burden is also felt by healthcare providers and insurance companies, which may hesitate to include the drug in their formularies or coverage plans, further hindering its widespread use. The high cost thus poses a challenge to dapagliflozin’s adoption and broader market penetration, particularly in underserved areas.
Adverse effects and safety concerns present a key challenge in the global dapagliflozin market, potentially limiting its broader use. Despite its effectiveness in treating diabetes, heart failure, and chronic kidney disease, dapagliflozin is linked to side effects such as urinary tract infections, genital infections, dehydration, and a heightened risk of diabetic ketoacidosis. Additionally, its impact on kidney function raises concerns, particularly in patients with pre-existing renal conditions, requiring ongoing monitoring to ensure patient safety. These safety issues can make healthcare providers hesitant to prescribe dapagliflozin, especially for patients with complex comorbidities or those at higher risk for these adverse effects. The need for continuous monitoring, coupled with the potential for increased healthcare costs, can complicate patient management and reduce adherence to treatment. While the therapeutic benefits of dapagliflozin are significant, addressing these safety concerns is crucial to improving its acceptance and use in diverse patient populations.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The market is segmented on the basis of indication, dosage strength, application, age group, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
Dosage Strength
Application
Age Group
End User
Distribution Channel
The market is analyzed and market size insights and trends are provided by country, indication, dosage strength, application, age group, end user, and distribution channel as referenced above.
The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
North America is expected to dominate the market due to the high prevalence of diabetes, heart failure, and chronic kidney disease, which significantly drive the demand for effective treatment options. Advanced healthcare infrastructure and favorable reimbursement policies further enhance patient access to dapagliflozin, supporting its adoption as a preferred therapy in managing these interconnected conditions.
Asia-Pacific is expected to be the fastest growing due to the rising prevalence of diabetes, particularly in rapidly urbanizing countries such as India and China, where lifestyle-related health issues are on the rise. Improving healthcare access, coupled with increasing healthcare expenditure in emerging markets, drives the adoption of advanced treatments such as dapagliflozin, addressing the growing need for effective diabetes and cardiovascular care.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Dapagliflozin Market Leaders Operating in the Market Are:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.